Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib

This publication has 54 references indexed in Scilit:

• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
  Science Translational Medicine, 2012
• PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
  British Journal of Cancer, 2011
• Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
  Drug Design, Development and Therapy, 2011
• Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen
  Chemical Biology & Drug Design, 2011
• Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
  Journal of Medicinal Chemistry, 2011
• Development of radiotracers for oncology – the interface with pharmacology
  British Journal of Pharmacology, 2011
• Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
  Cancer Research, 2011
• Treatment of Alcohols with Tosyl Chloride Does Not always Lead to the Formation of Tosylates
  Molecules, 2011
• Anaplastic lymphoma kinase: signalling in development and disease
  Biochemical Journal, 2009
• EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
  The American Journal of Pathology, 2009